Skip to main content

Divide and conquer: using patient-derived tumour organoids to dissect intra-tumour immune heterogeneity of non-small cell lung cancer

Project description

A holistic view on cancer immune evasion

Understanding anti-tumour immunity is central for the design of effective immunotherapy strategies. However, the clonal nature of tumours leads to heterogeneity in treatment response and even drug resistance. Scientists of the EU-funded TxImmuneOrganoids project propose to address this challenge through the development of appropriate patient-derived models. They will establish organoids from non-small cell lung cancer (NSCLC) patients and study their interaction with autologous or allogeneic T cells. Results will provide a holistic and mechanistic overview of immune surveillance and evasion in NSCLC. Moreover, identification of putative molecular determinants may open opportunities for novel anti-cancer interventions.


Net EU contribution
€ 224 933,76
1 Midland Road
NW1 1AT London
United Kingdom

See on map

London Inner London — West Camden and City of London
Activity type
Research Organisations
Other funding
€ 0,00